Correction to: Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis

Author unknown

Open source

DOI
10.1093/ofid/ofag603
Published
2026-09-29
Container
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ofid/ofag603,
  title = {Correction to: Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis},
  year = {2026},
  journal = {Open Forum Infectious Diseases},
  doi = {10.1093/ofid/ofag603},
  url = {https://doi.org/10.1093/ofid/ofag603}
}

RIS

TY  - JOUR
TI  - Correction to: Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis
PY  - 2026
JO  - Open Forum Infectious Diseases
DO  - 10.1093/ofid/ofag603
UR  - https://doi.org/10.1093/ofid/ofag603
ER  - 

APA

Correction to: Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis. (2026). Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag603

Source records